Trial Profile

A Phase II Study of IMC-A12 (Anti-IGF-I Receptor Monoclonal Antibody, NSC 742460) in Children With Relapsed/Refractory Solid Tumors

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cixutumumab (Primary)
Indications Adenocarcinoma; Brain cancer; Ewing's sarcoma; Liver cancer; Neuroblastoma; Neuroectodermal tumours; Osteosarcoma; Retinoblastoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Synovial sarcoma; Wilms' tumour
Focus Adverse reactions; Therapeutic Use

Most Recent Events

29 Mar 2015 Protocol has been amended to change in incl/excl, treatment arms and patient number.
01 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
04 Sep 2013 Planned End Date changed from 1 Sep 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com